IGF::OT::IGF Topic 090, Phase II, Devices to Close Ductus Arteriosus in Premature Infants IGF::OT::IGF
IGF::OT::IGF Topic 090, Phase II, Devices to Close Ductus Arteriosus in Premature Infants IGF::OT::IGF
批准号:
9581252
负责人:
PAUL LUBOCK
金额:
$199.96万
依托单位:
--
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-07-03 至 2019-07-02
关键词:
Animal ExperimentsAnimal ModelAnimalsCaringCase Report FormCathetersChronicClinicalClinical ProtocolsClinical TrialsCollaborationsDevelopment PlansDevice or Instrument DevelopmentDevicesDocumentationDuctus ArteriosusElementsEquipment MalfunctionFailureFatigueFreezingGeometryGoalsHumanImplantInformed ConsentIntramural ResearchInvestigationLaboratoriesLaboratory ResearchLicensingMarketingMarylandMechanicsModelingMorbidity - disease rateNational Heart, Lung, and Blood InstitutePatent Ductus ArteriosusPeripheralPhasePremature InfantPreparationReportingResearch DesignRiskSpecific qualifier valueSterilitySystemTestingTravelUnited States National Institutes of Healthbasebiomaterial compatibilityclinical developmentclinical materialcostdesignhemodynamicsin vivomeetingsminimally invasivemortalitypaymentprototyperesearch and developmentresearch clinical testingsafety testingtreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Summary
Premature infants with hemodynamically significant patent ductus arteriosus suffer increased mortality and significant morbidity. A minimally invasive, catheter based treatment strategy would be attractive.
Project Goals
The goal of the project is to develop an implantable patent ductus arteriosus closure device to be safely delivered through the peripheral vasculature of a premature infant. First, a prototype would be developed and tested in animals, and ultimately a clinical-grade device would undergo regulatory development for clinical testing at NIH.
Offerors are encouraged to include concrete milestones in their proposals, along with detailed research and development plans, risk analysis, and contingency plans, both for Phase I and Phase II.
It is recognized that available animal models may not match the desired human in vivo geometry of the device.
Offerors are advised to plan for travel to NHLBI in Bethesda Maryland, and are expected to plan meetings at project initiation, mid-project to determine what iteration is necessary, and at project completion.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金